Atossa Therapeutics (ATOS) Stock Price, News & Analysis

Company Overview

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $0.83 to $0.89
• 50-Day Range: $0.59 to $1.03
• 52-Week Range: $0.55 to $1.66
• Volume: 608,937 shs
• Average Volume: 786,272 shs
• Market Capitalization: $107.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.13
• Consensus Rating: Buy

Atossa Therapeutics Stock Analysis - MarketRank™

Atossa Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 649th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Atossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Atossa Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atossa Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atossa Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atossa Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.52% of the outstanding shares of Atossa Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Atossa Therapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Atossa Therapeutics has recently decreased by 6.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atossa Therapeutics does not currently pay a dividend.

Dividend Growth

Atossa Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.52% of the outstanding shares of Atossa Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Atossa Therapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Atossa Therapeutics has recently decreased by 6.55%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.63

News Sentiment

Atossa Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Atossa Therapeutics this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

10 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Atossa Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,890.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 7.60% of the stock of Atossa Therapeutics is held by insiders.

Percentage Held by Institutions

Only 12.74% of the stock of Atossa Therapeutics is held by institutions.

ATOS Stock Analysis - Frequently Asked Questions

How have ATOS shares performed this year?

Atossa Therapeutics' stock was trading at $0.9441 at the beginning of 2025. Since then, ATOS shares have decreased by 11.9% and is now trading at $0.8317.
View the best growth stocks for 2025 here.

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01.

When did Atossa Therapeutics' stock split?

Shares of Atossa Therapeutics reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Atossa Therapeutics' major shareholders?

Top institutional investors of Atossa Therapeutics include Charles Schwab Investment Management Inc. (0.33%), Goldman Sachs Group Inc. (0.15%), Nuveen LLC (0.13%) and Simplex Trading LLC. Insiders that own company stock include Jonathan Finn, Steven C Quay and H Lawrence Remmel.
View institutional ownership trends.

How do I buy shares of Atossa Therapeutics?

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Therapeutics investors own include Zomedica (ZOM), AUO (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/23/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATOS
• CIK: 1488039
• Web: atossatherapeutics.com
• Phone: (206) 588-0256
• Fax: 206-430-1288
• Employees: 8
• Year Founded: 2009

Price Target and Rating

• Average Stock Price Target: $7.13
• High Stock Price Target: $7.25
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +756.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,090,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.74%
• Return on Assets: -33.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.30
• Quick Ratio: 13.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 129,170,000
• Free Float: 116,240,000
• Market Cap: $107.43 million
• Optionable: Optionable
• Beta: 1.01